Sanofi, the French pharmaceutical giant, is making a bold move to amplify its presence in India with a substantial investment of 400 million euros ($437.24 million) in its Global Capacity Center (GCC) in Hyderabad by the decade’s end. Aiming to more than double its workforce over the next two years, the company is set to initially invest 100 million euros ($109.31 million) by next year, revealed Madeleine Roach, Executive Vice President of Business Operations, at a recent event.
Hyderabad’s GCC, already the largest among Sanofi’s global facilities, employs 1,000 people. This center is set to grow exponentially, with plans to boost its staff to 2,600 by 2026. Roach shared that the expansion would involve recruiting data scientists and engineers to enhance the digital team and harness the power of artificial intelligence.
Roach noted that the Hyderabad team at Sanofi collaborates effortlessly with partners in the U.S. and France, which significantly boosts confidence in their capabilities. The U.S., Sanofi’s top revenue market, relies heavily on the expertise fostered in Hyderabad. The facility is poised to handle a significant volume of documentation work for drug clinical trials, she added.
India’s domestic GCC market is on a trajectory to more than double to $110 billion by 2030, fueled by a skilled workforce and a conducive business environment, according to consulting firm EY. Roach also pointed out that beyond the rich talent pool, geopolitical shifts are steering Sanofi’s expansion in India, as pharmaceutical companies seek to reduce their dependency on China.
With this strategic investment, Sanofi is not just growing its footprint in India but also setting the stage for a future where innovation and collaboration drive the global pharmaceutical landscape.
